Theresa Heggie is the founder of Freeline. Latest round: Series C. Backed by Novo Holdings A/S, Eventide Asset Management, Wellington Management Company.
Theresa Heggie is the CEO of Freeline Therapeutics, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases. She took on this leadership role after the company's $120 million extended Series C financing round in 2020. Freeline is part of the UCL Tech Fund portfolio, with a focus on treating conditions such as Fabry Disease.
Full founder directory · Investor directory · Company funding database · Fundraising library